In a welcome move, Viatris saw its Relative Strength Rating improve from 69 to 74 on Monday.
IBD's proprietary rating measures price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves. See if Viatris can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Viatris is still within a buy zone after climbing above a 12.77 entry in a cup with handle. The proper buying range is up to 5% above the initial entry. Once a stock hits that benchmark, it's best to hold off investing and wait for it to set up another buying opportunity..
In terms of top and bottom line numbers, the company has posted rising EPS growth in each of the last two reports. Revenue growth has not followed the same trajectory, coming in at -5% last quarter.
Viatris holds the No. 4 rank among its peers in the Medical-Generic Drugs industry group. Teva Pharmaceutical ADR is the top-ranked stock within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
